Circulating miR-924, miR-98, and miR-1 were identified as potential biomarkers for detecting hypertrophic cardiomyopathy, demonstrating AUCs of 0.829, 0.866, and 0.866, respectively.
Case-Control (n=22)
No
Does the circulating transcriptome expression profile in PBMCs identify novel miRNA biomarkers in patients with hypertrophic cardiomyopathy?
The study identified three hub miRNAs (miR-924, miR-98, and miR-1) in PBMCs as potential diagnostic biomarkers for hypertrophic cardiomyopathy.
Effect estimate: AUC 0.866
BACKGROUND: Hypertrophic cardiomyopathy (HCM), one of the most common genetic cardiovascular diseases, but cannot be explained by single genetic factors. Circulating microRNAs (miRNAs) are stable and highly conserved. Inflammation and immune response participate in HCM pathophysiology, but whether the miRNA profile changes correspondingly in human peripheral blood mononuclear cells (PBMCs) with HCM is unclear. Herein, we aimed to investigate the circulating non-coding RNA (ncRNA) expression profile in PBMCs and identify potential miRNAs for HCM biomarkers. METHODS: A Custom CeRNA Human Gene Expression Microarray was used to identify differentially expressed (DE) mRNAs, miRNAs, and ncRNAs (including circRNA and lncRNA) in HCM PBMCs. Weighted correlation network analysis (WGCNA) was used to identify HCM-related miRNA and mRNA modules. The mRNAs and miRNAs from the key modules were used to construct a co-expression network. Three separate machine learning algorithms (random forest, support vector machine, and logistic regression) were applied to identify potential biomarkers based on miRNAs from the HCM co-expression network. Gene Expression Omnibus (GEO) database (GSE188324) and experimental samples were used for further verification. Gene set enrichment analysis (GSEA) and competing endogenous RNA (ceRNA) network was used to determine the potential functions of the selected miRNAs in HCM. RESULTS: We identified 1194 DE-mRNAs, 232 DE-miRNAs and 7696 DE-ncRNAs in HCM samples compared with normal controls from the microarray data sets. WGCNA identified key miRNA modules and mRNA modules evidently associated with HCM. We constructed a miRNA‒mRNA co-expression network based on these modules. A total of three hub miRNAs (miR-924, miR-98 and miR-1) were identified by random forest, and the areas under the receiver operator characteristic curves of miR-924, miR-98 and miR-1 were 0.829, 0.866, and 0.866, respectively. CONCLUSIONS: We elucidated the transcriptome expression profile in PBMCs and identified three hub miRNAs (miR-924, miR-98 and miR-1) as potential biomarkers for HCM detection.
Guo et al. (Fri,) conducted a case-control in Hypertrophic cardiomyopathy (n=22). miRNA biomarkers (miR-924, miR-98, miR-1) vs. Normal controls was evaluated on Diagnostic accuracy (AUC) of miR-98 and miR-1 for HCM detection (AUC 0.866). Circulating miR-924, miR-98, and miR-1 were identified as potential biomarkers for detecting hypertrophic cardiomyopathy, demonstrating AUCs of 0.829, 0.866, and 0.866, respectively.